From lab to global stage: Reforgene advances international patent portfolio for its novel CasRm gene editing system
Reforgene's proprietary, efficient, safe and compact novel CasRm gene editing system (derived from the CRISPR-Cas13 family), which holds independent intellectual property, has seen its PCT patent application (Application No. PCT/CN2023/115093) successfully enter China and the United States, with plans to expand to more than 10 countries or regions in the future. The patent family has global freedom-to-operate (FTO) value and covers CasRm and its mutants, homologous proteins, and various RNA editing applications.
Building on its original TIPBAIG general technology platform, Reforgene mines genomic big data through machine learning algorithms, and combines AI-driven protein structure analysis with downstream systematic molecular biology applications to enable high-throughput discovery and optimization of CRISPR-Cas nucleases and related functional proteins for gene editing. CasRm is a novel CRISPR-Cas13 gene editing tool that is highly efficient, has an extremely low off-target rate and a compact structure, with excellent RNA-targeting editing activity. In particular, its editing efficiency on multiple RNA targets surpasses that of CasRx (RfxCas13d), the high-activity tool currently used by mainstream U.S. research institutions. In addition, CasRm is about 70 amino acids smaller than CasRx, further improving flexibility in drug design and making it more suitable for AAV delivery. With significant advantages on multiple fronts, CasRm-based gene editing medicines show better potential in efficacy and safety.
Gene editing technology has broad application prospects in the life sciences. The CasRm system can be widely applied in human disease drug development, virus clearance, gene function research, transcriptomics research, RNA labeling and detection, disease diagnosis, crop improvement, veterinary drug development, synthetic biology and biosensor design, among other fields. Reforgene is currently applying the CasRm system to drug development for multiple diseases, including age-related macular degeneration, and multiple research results have been presented at the 27th ASGCT Annual Meeting and the IAPRD 2024 Congress.
Based on the development of the CasRm system, Reforgene has built an extensive patent portfolio around its underlying technology and drug targets, currently holding 9 patent families and a total of 19 patent applications, including 6 PCT applications, providing strong intellectual property protection for the commercialization of gene editing technology.
As one of the few innovative drug companies worldwide with underlying CRISPR patent technology, Reforgene has achieved notable results in gene editing tool innovation. The entry of the CasRm patent application into China and the United States is another major breakthrough in Reforgene's technological innovation, further expanding its intellectual property portfolio in the gene editing field. To date, Reforgene holds 69 invention patent families worldwide, involving 136 invention patent applications and 18 granted patents, covering Cas9, Cas12, Cas13 and base editing systems, forming a comprehensive and robust intellectual property network.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. Reforgene has a high-caliber team that applied gene editing to explore the treatment of genetic diseases at an early stage internationally, and has accumulated pioneering achievements in hematology, ophthalmology and other disease areas, with strong technical capabilities in gene editing tool innovation, drug development strategy, novel animal model construction, and multi-level efficacy and safety assessment, operating both in vivo and ex vivo drug development. Reforgene's mission is to deliver accessible, curative medicines for patients with serious diseases through innovative genetic technologies. The company currently has pipeline programs across genetic diseases, complex diseases and oncology. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.